BRPI0913349A2 - derivados de ureia e sulfamida macrocíclicos como inibidores de tafia - Google Patents

derivados de ureia e sulfamida macrocíclicos como inibidores de tafia

Info

Publication number
BRPI0913349A2
BRPI0913349A2 BRPI0913349A BRPI0913349A BRPI0913349A2 BR PI0913349 A2 BRPI0913349 A2 BR PI0913349A2 BR PI0913349 A BRPI0913349 A BR PI0913349A BR PI0913349 A BRPI0913349 A BR PI0913349A BR PI0913349 A2 BRPI0913349 A2 BR PI0913349A2
Authority
BR
Brazil
Prior art keywords
tafia inhibitors
sulfamide derivatives
macrocyclic urea
macrocyclic
urea
Prior art date
Application number
BRPI0913349A
Other languages
English (en)
Portuguese (pt)
Inventor
Andreas Evers
Anja Globisch
Christopher Kallus
Herman Schreuder
Mark Broenstrup
Michael Wagner
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of BRPI0913349A2 publication Critical patent/BRPI0913349A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/01—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having one nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0913349A 2008-06-06 2009-05-22 derivados de ureia e sulfamida macrocíclicos como inibidores de tafia BRPI0913349A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290520 2008-06-06
PCT/EP2009/003650 WO2009146802A1 (de) 2008-06-06 2009-05-22 Makrocyclische harnstoff- und sulfamidderivate als inhibitoren von tafia

Publications (1)

Publication Number Publication Date
BRPI0913349A2 true BRPI0913349A2 (pt) 2015-11-24

Family

ID=39800716

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0913349A BRPI0913349A2 (pt) 2008-06-06 2009-05-22 derivados de ureia e sulfamida macrocíclicos como inibidores de tafia

Country Status (34)

Country Link
US (5) US8580777B2 (enExample)
EP (1) EP2300462B1 (enExample)
JP (1) JP5531011B2 (enExample)
KR (1) KR101673886B1 (enExample)
CN (1) CN102056922B (enExample)
AR (1) AR072007A1 (enExample)
AU (1) AU2009254257B2 (enExample)
BR (1) BRPI0913349A2 (enExample)
CA (1) CA2726554C (enExample)
CL (1) CL2009001358A1 (enExample)
CO (1) CO6321271A2 (enExample)
CR (1) CR11807A (enExample)
CY (1) CY1115604T1 (enExample)
DK (1) DK2300462T3 (enExample)
DO (1) DOP2010000363A (enExample)
EC (1) ECSP10010655A (enExample)
ES (1) ES2494390T3 (enExample)
HN (1) HN2010002558A (enExample)
HR (1) HRP20140787T1 (enExample)
IL (1) IL209772A (enExample)
MA (1) MA32322B1 (enExample)
MX (1) MX2010012793A (enExample)
NI (1) NI201000203A (enExample)
NZ (1) NZ589671A (enExample)
PL (1) PL2300462T3 (enExample)
PT (1) PT2300462E (enExample)
RU (1) RU2502736C2 (enExample)
SI (1) SI2300462T1 (enExample)
SV (1) SV2010003747A (enExample)
TW (1) TWI455928B (enExample)
UA (1) UA104002C2 (enExample)
UY (1) UY31868A (enExample)
WO (1) WO2009146802A1 (enExample)
ZA (1) ZA201007719B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010012793A (es) 2008-06-06 2010-12-14 Sanofi Aventis Derivados de urea macrociclicos y de sulfamida como inhibidores de tafia.
CA2727925A1 (en) 2008-06-23 2009-12-30 Astrazeneca Ab New heterocyclic carboxamides for use as thrombin inhibitors
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
CA2863892C (en) * 2012-03-06 2016-08-30 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
RU2015156612A (ru) * 2013-06-10 2017-07-17 Санофи Макроциклические производные мочевины в качестве ингибиторов tafia, их получение и их применение в качестве фармацевтических средств
UY35809A (es) * 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
CN103755852B (zh) * 2013-12-18 2015-12-09 湖北大学 线型聚苯乙烯支载(4s)-(4’-氧苄基)-2-正丁基环磺酰胺及其制备方法和用途
CN106631832A (zh) * 2016-10-08 2017-05-10 帕潘纳(北京)科技有限公司 一种氨基醚类化合物的制备方法
US10411291B2 (en) * 2017-03-22 2019-09-10 Nanotek Instruments, Inc. Multivalent metal ion battery having a cathode layer of protected graphitic carbon and manufacturing method

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU667995B2 (en) 1993-02-15 1996-04-18 Bayer Aktiengesellschaft New pseudopeptides having an antiviral action
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
US5888971A (en) * 1996-02-20 1999-03-30 Ortho Pharmaceutical Corporation, Inc. Macrocyclic peptides useful in the treatment of thrombin related disorders
AU749132B2 (en) 1997-08-28 2002-06-20 Biovitrum Ab Inhibitors of protein tyrosine phosphatase
US6124278A (en) * 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response
US6482921B1 (en) 1999-01-28 2002-11-19 Essential Therapeutics, Inc. Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use
DE60042585D1 (de) * 2000-02-29 2009-09-03 Univ Firenze 3-Aza-6,8-dioxabicycloÄ3.2.1Üoctane und Analoga sowie diese enthaltende kombinatorische Bibliotheken
DE102004020186A1 (de) * 2004-04-22 2005-11-17 Aventis Pharma Deutschland Gmbh Heterocyclylessigsäuren als Inhibitoren von TAFla
NZ577312A (en) 2006-12-06 2012-02-24 Sanofi Aventis Urea and sulfamide derivatives as tafia inhibitors
MX2010012793A (es) 2008-06-06 2010-12-14 Sanofi Aventis Derivados de urea macrociclicos y de sulfamida como inhibidores de tafia.

Also Published As

Publication number Publication date
IL209772A (en) 2016-04-21
NI201000203A (es) 2011-09-29
ECSP10010655A (es) 2011-01-31
RU2010154089A (ru) 2012-07-20
US20110178130A1 (en) 2011-07-21
KR101673886B1 (ko) 2016-11-08
RU2502736C2 (ru) 2013-12-27
IL209772A0 (en) 2011-02-28
ZA201007719B (en) 2011-07-27
CR11807A (es) 2011-02-16
CA2726554C (en) 2015-02-24
SV2010003747A (es) 2011-03-15
MX2010012793A (es) 2010-12-14
AR072007A1 (es) 2010-07-28
HRP20140787T1 (hr) 2014-11-21
US8722655B2 (en) 2014-05-13
WO2009146802A1 (de) 2009-12-10
JP5531011B2 (ja) 2014-06-25
US20140039011A1 (en) 2014-02-06
CL2009001358A1 (es) 2009-11-27
KR20110020795A (ko) 2011-03-03
DK2300462T3 (da) 2014-08-18
HN2010002558A (es) 2012-08-28
AU2009254257B2 (en) 2013-11-21
JP2011521981A (ja) 2011-07-28
EP2300462B1 (de) 2014-05-21
CN102056922B (zh) 2013-11-20
AU2009254257A1 (en) 2009-12-10
HK1152936A1 (en) 2012-03-16
PL2300462T3 (pl) 2014-10-31
US20140206760A1 (en) 2014-07-24
US9688645B2 (en) 2017-06-27
SI2300462T1 (sl) 2014-09-30
MA32322B1 (fr) 2011-05-02
TW201008917A (en) 2010-03-01
EP2300462A1 (de) 2011-03-30
NZ589671A (en) 2012-03-30
US9309207B2 (en) 2016-04-12
US20160024033A1 (en) 2016-01-28
TWI455928B (zh) 2014-10-11
DOP2010000363A (es) 2010-12-15
UA104002C2 (ru) 2013-12-25
CA2726554A1 (en) 2009-12-10
US9126955B2 (en) 2015-09-08
UY31868A (es) 2010-01-05
ES2494390T3 (es) 2014-09-15
PT2300462E (pt) 2014-08-05
CN102056922A (zh) 2011-05-11
US8580777B2 (en) 2013-11-12
CO6321271A2 (es) 2011-09-20
US20160251324A1 (en) 2016-09-01
CY1115604T1 (el) 2017-01-04

Similar Documents

Publication Publication Date Title
FR20C1030I2 (fr) Inhibiteurs de beta-lactamase
BRPI0906625A2 (pt) Derivados de tio-2-amino-quinolina-6-substituída úteis como inibidores da beta-secretase (bace)
BRPI0914223A2 (pt) derivados de tiofeno ou tiazol e seus usos como inibidores de p13k
BRPI0912431A2 (pt) Combinações de substâncias ativas sinergísticas
BRPI0812825A2 (pt) Derivados ftalazinona como inibidores de parp-1
BRPI0911444A2 (pt) benzoimidazóis como inibidores de prolil hidroxilase
BRPI0915991A2 (pt) derivados de sulfamida substituída
HRP20190016T1 (hr) Heterociklički spojevi i njihova upotreba
PT2860179T (pt) Derivados de pirazolo-piridina como inibidores de nadph-oxidase
BRPI1009333A2 (pt) inibidores de beta-secretase
BRPI0911118A2 (pt) composto e compisições como moduladores de atividade de gpr119
BRPI0906598A2 (pt) Oxim derivattivos como inibidores hsp90
BRPI1015568A2 (pt) derivados de imidazolidin-2-ona 1,3-dissubstituído como inibidores de cyp 17.
BRPI0820544A2 (pt) 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase
BRPI0814256A2 (pt) Inibidores de tetrahidropiranocromeno gama secretase
BRPI0815135A2 (pt) Derivados de azepina como inibidores de gama secretase.
BRPI1016117A2 (pt) derivados de isoxazol-isoxazol e isoxasol-isotiazol.
BRPI0812753A2 (pt) Combinações de substância ativas acaricidas
PT2513105E (pt) Derivados de 2-arilimidazole como inibidores da enzima pde10a
BR112012010242A2 (pt) derivados de heteroarilpiperidina e heteroarilpiperazina
BRPI0906352A2 (pt) Derivado de tiazol e uso do mesmo como inibidores de vap-1
IL209772A (en) Macrocyclic urea derivatives and sulfonamide derivatives as tafia inhibitors
BRPI0816806A2 (pt) Derivados de azaciclil-isoquinolinona e isoindolinona como antagonista de histamina-3
BRPI0922799A2 (pt) lactamas como inibidores da beta secretase
BRPI0920247A2 (pt) benzimidazóis heterocíclicos como moduladores de trpm8.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements